Proto-Oncogene Proteins

"Proto-Oncogene Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.

Descriptor ID	D011518
MeSH Number(s)	D12.776.624.664.700
Concept/Terms	Proto-Oncogene Proteins Proto-Oncogene Proteins Proto Oncogene Proteins Proto-Oncogene Products, Cellular Cellular Proto-Oncogene Products Proto Oncogene Products, Cellular Proto Oncogene Proteins, Cellular c-onc Proteins c onc Proteins Cellular Proto-Oncogene Proteins Cellular Proto Oncogene Proteins Proto-Oncogene Proteins, Cellular

Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Neoplasm Proteins [D12.776.624]
Oncogene Proteins [D12.776.624.664]
Proto-Oncogene Proteins [D12.776.624.664.700]

Below are MeSH descriptors whose meaning is related to "Proto-Oncogene Proteins".

Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Proto-Oncogene Proteins" by people in this website by year, and whether "Proto-Oncogene Proteins" was a major or minor topic of these publications.

Bar chart showing 108 publications over 26 distinct years, with a maximum of 9 publications in 2004

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1992	2	0	2
1993	4	0	4
1994	7	0	7
1995	4	1	5
1996	7	1	8
1997	1	3	4
1999	1	1	2
2000	2	0	2
2001	1	2	3
2002	3	3	6
2003	2	5	7
2004	1	8	9
2005	6	2	8
2007	2	1	3
2008	2	1	3
2009	3	2	5
2010	1	3	4
2011	3	1	4
2012	2	3	5
2013	3	1	4
2014	1	2	3
2015	1	2	3
2016	3	0	3
2017	1	0	1
2020	2	0	2
2021	1	0	1

Below are the most recent publications written about "Proto-Oncogene Proteins" by people in Profiles.

Kashyap D, Baral B, Jakhmola S, Singh AK, Jha HC. Helicobacter pylori and Epstein-Barr Virus Coinfection Stimulates Aggressiveness in Gastric Cancer through the Regulation of Gankyrin. mSphere. 2021 10 27; 6(5):e0075121.

View in: PubMed
Maiti GP, Sinha S, Mahmud H, Boysen J, Mendez MT, Vesely SK, Holter-Chakrabarty J, Kay NE, Ghosh AK. SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis. Blood Cancer J. 2021 05 17; 11(5):93.

View in: PubMed
Sinha S, Secreto CR, Boysen JC, Lesnick C, Wang Z, Ding W, Call TG, Kenderian SJ, Parikh SA, Warner SL, Bearss DJ, Ghosh AK, Kay NE. Upregulation of AXL and ß-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance. Blood Cancer J. 2021 02 18; 11(2):37.

View in: PubMed
Vuong HG, Nguyen TQ, Nguyen HC, Nguyen PT, Ho ATN, Hassell L. Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis. Target Oncol. 2020 10; 15(5):589-598.

View in: PubMed
Loontiens S, Vanhauwaert S, Depestel L, Dewyn G, Van Loocke W, Moore FE, Garcia EG, Batchelor L, Borga C, Squiban B, Malone-Perez M, Volders PJ, Olexiouk V, Van Vlierberghe P, Langenau DM, Frazer JK, Durinck K, Speleman F. A novel TLX1-driven T-ALL zebrafish model: comparative genomic analysis with other leukemia models. Leukemia. 2020 12; 34(12):3398-3403.

View in: PubMed
Fuentes-Mattei E, Bayraktar R, Manshouri T, Silva AM, Ivan C, Gulei D, Fabris L, Soares do Amaral N, Mur P, Perez C, Torres-Claudio E, Dragomir MP, Badillo-Perez A, Knutsen E, Narayanan P, Golfman L, Shimizu M, Zhang X, Zhao W, Ho WT, Estecio MR, Bartholomeusz G, Tomuleasa C, Berindan-Neagoe I, Zweidler-McKay PA, Estrov Z, Zhao ZJ, Verstovsek S, Calin GA, Redis RS. miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2. JCI Insight. 2020 01 16; 5(1).

View in: PubMed
Dey A, Xiong X, Crim A, Dwivedi SKD, Mustafi SB, Mukherjee P, Cao L, Sydorenko N, Baiazitov R, Moon YC, Dumble M, Davis T, Bhattacharya R. Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol Cancer Ther. 2018 01; 17(1):39-49.

View in: PubMed
Banerjee Mustafi S, Aznar N, Dwivedi SK, Chakraborty PK, Basak R, Mukherjee P, Ghosh P, Bhattacharya R. Mitochondrial BMI1 maintains bioenergetic homeostasis in cells. FASEB J. 2016 12; 30(12):4042-4055.

View in: PubMed
Orme JJ, Du Y, Vanarsa K, Mayeux J, Li L, Mutwally A, Arriens C, Min S, Hutcheson J, Davis LS, Chong BF, Satterthwaite AB, Wu T, Mohan C. Heightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE. Clin Immunol. 2016 08; 169:58-68.

View in: PubMed
Eskander RN, Ali S, Dellinger T, Lankes HA, Randall LM, Ramirez NC, Monk BJ, Walker JL, Eisenhauer E, Hoang BH. Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2016 Jan; 26(1):125-32.

View in: PubMed

People

Explore

Similar Concepts

Top Journals